IMC Logo.jpg
Immuron US DoD Naval Medical Research Center Submits IND Application for New Campylobacter ETEC Therapeutic
May 11, 2022 06:00 ET | Immuron Limited
Key Points US Naval Medical Research Centre (NMRC) submits IND application to the U.S. Food and Drug administration (FDA)Two human phase II clinical trials to be conducted. One trial will focus on...
IMC Logo.jpg
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
May 09, 2022 06:00 ET | Immuron Limited
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the...
IMC Logo.jpg
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
April 19, 2022 07:33 ET | Immuron Limited
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND)...
IMC Logo.jpg
Immuron Receives A$6.2 Million Award from U.S. DoD to Clinically Evaluate a Military Strength Dosing Regimen for Travelan
January 12, 2022 06:00 ET | Immuron Limited
Key Highlights: Immuron Awarded AU $4.8 (USD $3.43) million funding by the U.S. Department of Defense for TravelanU.S Naval Medical Research Center Received AU $1.4 (USD $1.02) million funding to...
IMC Logo.jpg
US DoD Uniformed Services University Travelers’ Diarrhea Clinical Update
November 15, 2021 06:00 ET | Immuron Limited
Key Points Manufacture of investigational medical products to support the Uniformed Services University (USU) clinical program to evaluate the efficacy of Travelan® and two other non-antibiotic OTC...
IMC Logo.jpg
US DoD Naval Medical Research Center Clinical Update
November 10, 2021 06:00 ET | Immuron Limited
Key Points Manufacture of investigational medical products to support the US Naval Medical Research Centre (NMRC) clinical programs completed.IND submission to the U.S. Food and Drug administration...
IMC Logo.jpg
US DoD Naval Medical Research Center Reports Positive Immunological Responses to Vaccine
November 11, 2020 06:00 ET | Immuron Limited
Key Points NMRC demonstrated functional antibodies in new oral therapeutic targeting Campylobacter and ETECImmuron executes a Research Agreement with PCI Clinical Services to manufacture drug...
IMC Logo.jpg
Immuron Travelers’ Diarrhea Market Update
October 12, 2020 06:00 ET | Immuron Limited
Key Points Immuron’s IMM-124E IND Program recommencesUniformed Services University to recommence planned Travelers’ Diarrhea clinical studyCOVID-19 - Consultancy Agreement with Infectious Disease...
IMC Logo.jpg
US DoD Naval Medical Research Center Receives FDA Guidance on the clinical development plans for new oral therapeutic
July 20, 2020 06:00 ET | Immuron Limited
Key Points NMRC received guidance from the FDA on the development of a new oral therapeutic targeting Campylobacter and ETEC Two human phase II clinical trials to be conducted in 2021One trial will...
IMC Logo.jpg
Immuron Partners with CSIRO to produce a new oral therapeutic for clinical evaluation by the US Department of Defense
June 19, 2020 06:00 ET | Immuron Limited
Key Points Immuron executes a Research Agreement with The Henry M. Jackson Foundation for Advancement of Military Medicine Inc.Immuron executes a Research Agreement with CSIRO to develop a new oral...